MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Sells 192,303 Shares of Moderna, Inc. (NASDAQ:MRNA)

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. cut its holdings in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 65.1% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 103,018 shares of the company's stock after selling 192,303 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.'s holdings in Moderna were worth $4,256,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of the business. Wilmington Savings Fund Society FSB raised its position in shares of Moderna by 295.0% during the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company's stock valued at $33,000 after buying an additional 587 shares during the period. Compass Planning Associates Inc acquired a new position in shares of Moderna in the fourth quarter worth $37,000. Venturi Wealth Management LLC grew its stake in shares of Moderna by 286.2% during the fourth quarter. Venturi Wealth Management LLC now owns 896 shares of the company's stock worth $37,000 after purchasing an additional 664 shares in the last quarter. Crowley Wealth Management Inc. acquired a new position in shares of Moderna during the fourth quarter worth $41,000. Finally, Itau Unibanco Holding S.A. grew its stake in shares of Moderna by 51.2% during the fourth quarter. Itau Unibanco Holding S.A. now owns 1,013 shares of the company's stock worth $42,000 after purchasing an additional 343 shares in the last quarter. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Moderna Stock Up 3.6%

MRNA stock traded up $0.92 during trading hours on Thursday, hitting $26.72. The company's stock had a trading volume of 11,272,311 shares, compared to its average volume of 7,992,642. The stock has a 50 day moving average price of $27.23 and a two-hundred day moving average price of $34.81. The company has a market capitalization of $10.33 billion, a PE ratio of -2.88 and a beta of 1.99. Moderna, Inc. has a 12 month low of $23.15 and a 12 month high of $170.47.

Moderna (NASDAQ:MRNA - Get Free Report) last posted its earnings results on Thursday, May 1st. The company reported ($2.52) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.92) by $0.40. Moderna had a negative net margin of 110.04% and a negative return on equity of 28.74%. The business had revenue of $108.00 million for the quarter, compared to analyst estimates of $130.35 million. During the same period last year, the business posted ($3.07) EPS. Moderna's revenue was down 35.3% compared to the same quarter last year. Sell-side analysts expect that Moderna, Inc. will post -9.61 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. Morgan Stanley reduced their price target on shares of Moderna from $39.00 to $32.00 and set an "equal weight" rating for the company in a research report on Wednesday, April 9th. Royal Bank of Canada cut their price target on shares of Moderna from $32.00 to $28.00 and set a "sector perform" rating for the company in a report on Friday, May 2nd. The Goldman Sachs Group cut shares of Moderna from a "buy" rating to a "neutral" rating and cut their price target for the stock from $99.00 to $51.00 in a report on Wednesday, January 29th. William Blair restated a "market perform" rating on shares of Moderna in a research report on Thursday, April 17th. Finally, Barclays lowered their price target on shares of Moderna from $45.00 to $40.00 and set an "equal weight" rating on the stock in a research report on Friday, May 2nd. Four equities research analysts have rated the stock with a sell rating, fifteen have issued a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $53.58.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.